Молекулярно-биологические маркеры метастазирования и прогноза при раке толстой кишки
Диссертация
Исследование особенностей биологического поведения опухоли является в настоящее время одной из наиболее актуальных проблем онкологии. Основой для выделения клинически значимых молекулярных факторов послужило открытие наблюдаемых в процессе развития и прогрессии опухоли структурных и функциональных изменения онкогенов и генов-супрессоров. Особенности экспрессии кодируемых этими генами белков могут… Читать ещё >
Список литературы
- Аксель Е.М., Давыдов М. И. Статистика заболеваемости и смертности от злокачественных новообразований в 2000 г. // Злокачественные новообразования в России и странах СНГ в 2000 г. М. — 2002. — С. 85−106.
- Аксель Е.М., Давыдов М. И., Ушакова Т. Н. Злокачественные новообразования желудочно-кишечного тракта: основные статистические показатели и тенденции // Соврем, онкол. 2001. — Том 3, № 4. — С. 10−22.
- Ананьев B.C., Царюк В. Ф. Рак ободочной кишки. // Энциклопедия клинической онкологии. Ред. Давыдов М. И. М. — 2004. — С. 305−310.
- Аруин Л.И., Капуллер Л. Л., Исаков В. А. Морфолгическая диагностика болезней желудка и кишечника. // М. — 1998. — 483С.
- Барсуков Ю.А., Кныш В. И. Современные возможности лечения колоректального рака. // Соврем, онкол. — 2006. Том 8, № 2. — С.
- Барсуков Ю.А., Николаев А. В., Перевощиков А. Г. Рак прямой кишки. // Энциклопедия клинической онкологии. Ред. Давыдов М. И. М — 2004. С.311−318.
- Вашакмадзе Л.А., Хомяков В. Н., Сидоров Д. В. Диагностика и лечение рака прямой кишки: современное состояние проблемы. // Российский онкол. журнал. 1999.-Том 6, С. 47−54.
- Герштейн Е.С., Кушлинский Н. Е. Активаторы плазминогена урокиназного и тканевого типов и их ингибитор PAI-1 в опухолях человека. // Бюлл. Эксп. Биол. и Мед. — 2001. Тот 131. № 1.-С.81−88.
- Герштейн Е.С., Кушлинский Н. Е. Тканевые маркеры как факторы прогноза при раке молочной железы. // Практ. онкол. 2002. — Том 3, № 1. — С. 38 — 45.
- П.Давидсон Б., Райх Р., Рисберг Б., Несланд Я. М. Биологическая роль и регуляция матричных металлопротеиназ при раке. // Архив патол. 2002. — Том 64, № 3.-С. 47−53.
- Давыдов М.Н., Аксель Е. Н. Статистика злокачественных новообразований в России и странах СНГ (состояние онкологической помощи, заболеваемость и смертность). // М. 2002.
- З.Давыдов М. И., Аксель Е. М. Злокачественные новообразования в России и странах СНГ в 2003 году. // М 2005.
- М.Зайратьянц О. В., Колобов С. В., Акопян И. Г. с соавт. Особенности экспрессии рецепторов эстрогенов, прогестерона и HER-2 клетками рака молочной железы. // Архив патол. 2004. — Том 66, № 5. — С. 9−12.
- Иванов А. А., Гладских О. П., Кузнецова А. В., Данилова Т. И. Межклеточные и клеточно-матриксные взаимодействия в патологии. // Мол. Мед. 2005. — № 2. — С. 16−20.
- Имянитов Е.Н., Черница О. И., Иванова О. А. с соавт. Амплификация онкогена ERBB-2(HER-2/NEU) в опухолях молочной железы прогностический маркер вероятности рецидива // Экспер. опкол. 1992. Том 14, № 4. — С. 25 — 29.
- Имянитов Е.Н. Кпинико-молекулярные аспекты колоректального рака: этиопатогенез, профилактика, индивидуализация лечения. // Практ. оикол. — 2005. Том 6, N2. — С. 65 — 70.
- Клишо Е.В., Кондакова И. В., Чойнзонов ЕЛ. с соавт. Прогностическая значимость протеаз у больных плоскоклеточными карциномами головы и шеи. // Бюлл. СО РАМН. 2005. — № 2 (116). — С.82−91.
- Коган Е. А., Угрюмов Д. А. Соотношение процессов пролиферации и клеточной гибели в немелкоклеточном раке легкого с железистой дифференцировкой на разных стадиях опухолевой прогрессии. II Архив патол. -2002. Том 64, № 1. — С. 33−37.
- Колесник А.П., Паламарчук И. Д., Сидоренко A.M. Молекулярные маркеры прогрессирования колоректального рака. // Онкология. 2006.- Том 8, № 1. — С. 13−17.
- Копнин Б.П. Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза (обзор). // Биохимия. — 2000. -Том 65,-С. 5−33.
- Корсакова Н. А. Особенности экспрессии Е-кадхерина, муцина-2 и Ki-67 в аденокарциномах толстой кишки. // Архив патол. — 2003. Том 65, — № 5. — С. 15−18.
- Кушлинский Н.Е., Герштейн Е. С. Современные возможности молекулярно-биохимических методов оценки биологического «поведения» рака молочной железы // Вести. РАМН. 2001. — № 9. — С. 65 — 70.
- Кушлинский Н.Е., Бритвин Т. А., Аббасова С. Г. с соавт. Растворимый Fas-антиген в сыворотке крови больных раком толстой кишки. // Бюлл. Эксп. Биол. и Мед. 2001. — Том 131, № 4. — С. 430−434.
- Кушлинский Н.Е., Ориновский М. Б., Гуревич J1.E. с соавт. Экспрессия молекулярно-биологических маркеров (Ki-67, PCNA, Bcl-2, ВАХ, BclX, VEGF) в опухолях молочной железы. // Бюлл. Эксп. Биол. и Мед. —2004. Том 137, — № 2.-С. 206−210
- Лазарев А.Ф., Климачев В. В., Авдалян A.M. с соавт. Экспрессия Ki-67 и р53 при дисплазии и раке желудка. И Архив патол. 2006. — Том 68, № 3. — С. 6−10.
- Леенман Е. Е., Кочурова Н. В., Белогурова М. Б., Пожарисский К. М. Иммуногистохимическое исследование мелкоклеточных сарком и факторов (nm23, CD44), прошозирующих их метастазирование у детей. И Архив патол. -2003. Том 65, — № 1. — С. 21−27.
- Лукашина М. И., Глухова Е. И., Жукова Л. Г. с соавт. Экспрессия Her-2/neu, Ki-67 и плоидность при раке молочной железы. II Архив патол. 2003. — Том 65, № 5.-С. 25−29.
- Лушннков Е. Ф., Абросимов А. Ю. Гибель клетки (апоптоз). — М. 2001.32,Обухова В. В., Белушкина Н. Н., Макарова О. В. с соавт. Система FAS/FASL при новообразованиях желудка и толстой кишки // Мол. Мед. — 2004. № 2. — С. 49−54.
- Патютко Ю.И., Чучуев Е. С., Котельников А. Г. с соавт. Синхронные операции при метастатическом раке печени. // Хирургия. — 2006. № 5. — С.15−19.
- Петров С.В., Раскнн Г. А., Хасанов Р. Ш. Новая гипотеза о роли онкогена с-егЬВ2 в профессии рака молочной железы. // Бюлл. Эксп. Биол. и Мед. — 2006. -Том 142, № 7.- С. 106−110.
- Перевощиков А.Г. Гистологическая и ультраструктурная характеристика колоректального рака. // Рак ободочной и прямой кишки. Ред. Кныш В. И. М. -1997. — С. 20 -44.
- Пожарисский К.М., Леенман Е. Е. Значение иммуногистохимических методик для определения характера лечения и прогноза опухолевых заболеваний. II Архив патол. — 2000. Том 62, № 5. — С. 3−11.
- Пожарисский К.М., Леенман Е. Е. Прогностическое и предсказательное значение иммуногистохимических маркеров. // Руководство по шшуногистохшшческой диагностике опухолей человека. Ред. Петров С. В. и Н. Т. Райхлин. Казань. — 2004. — С 310−329.
- Пожарисский К.М., Самсонова Е. А., Тен В.П. с соавт. Иммуногистохимический профиль эндометриоидной аденокарцнномы тела матки: ER, PR, HER-2, Ki-67 и их прогностическое значение. // Архив патол. -2005. Том 68, № 2.-С. 13−17.
- Портянко А. С., Черствой Е. Д. Система Fas/FasL и ее значение для регуляции взаимоотношений опухоли и иммунной системы при папиллярном раке щитовидной железы у детей и подростков. // Архив патол. 2003. — Том. 65.- № 4. -С. 14−18.
- Ровенский Ю.А. Клеточные и молекулярные механизмы опухолевой инвазии II Биохимия. 1998. — Том 63, вып. 9. — С. 1204 — 1221.
- Снарская Е. С., Молочков В. А., Франк Г. А., Завалишина JI. Э. Матриксные металлопротеиназы и их тканевые ингибиторы при базально-клеточном и метатипическом раке кожи. II Архив патол. 2005. — Том 67, — № 3. — С. 14−17.
- Соловьева Н.И. Матриксные металлопротеиназы и их биологические функции. II Ж. Биоорганич. химии. 1998. — № 24. — С. 217−226.
- Степанова Е. В., Харатишвили Т. К., Личиницер М. Р. С соавт. Прогностическое значение экспрессии р53, HER2/neu, Ki-67 и VEGF в хондросаркомах. // Архив патол. 2002. — Том 64, — № 6. — С. 9−13.
- Трапезников Н.Н., Аксель Е. М. Заболевания злокачественными новообразованиями и смертность от них населения стран СНГ в 1998 году. // М. -2001.
- Франк Г. А., Завалишина Л. Э., Андреева Ю. Ю. Состояние внеклеточного матрикса и маркеры адгезии в уротелиальном раке мочевого пузыря. // Архив патол. 2005. — Том 67, № 3. — С. 11−14.
- Чипышева Т.А., Гельштейн В. И., Ермилова В. Д. с соавт. Экспрессия молекул межклеточной адгезии Е-кадхерина и b-катенина в инфильтративных карциномах молочной железы. II Архив патол. 2003. — Том 65, № 3. — С. 3−7.
- Abdel-Wahed М.М., Asaad N.Y., Aleskandarany М. Expression of matrix metalloproteinase-2 in renal cell carcinoma. // J. Egypt. Natl. Cane. Inst. 2004. -Vol. 16.-N3.-P. 168- 177.
- Aglund K., Rauvala M., Puistola U. et al. Gelatinases A and В (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. // Gynecol. Oncol. 2004. — Vol. 94. — N 3. — P. 699 — 704.
- Ahmed F.E. Development of novel diagnostic and prognostic molecular markers for sporadic colon cancer. // Expert Review of Molecular Diagnostics. 2005. — Vol. 5.-Vol.3.-P. 337−352.
- Ahmed F.E. Molecular markers that predict response to colon cancer therapy. // Expert Review of Molecular Diagnostics. 2005. — Vol.5. — N 3. — P. 353 — 375.
- Ahmed F.E., Vos P.W., Holbert D. Modeling survival in colon cancer: a methodological review. // Mol. Cancer. 2007. — Vol. 6. — N 1. — P. 15.
- Aldrighetti L., Castoldi R., Di Palo S., et al. Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases. // Chir Ital. 2005. -Vol. 57. — N 5 — P. 555−570.
- Allegra C.J., Parr A.L., Wold L.E. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki67 in patients with locally advanced colon cancer. H J. Clin. Oncol. 2002. — Vol. 20. -N 1. — P. 1735−1743.
- Ambiru S., Miyazaki M., Isono Т., et al. Hepatic resection for colorectal metastases: analysis of prognostic factors. // Dis. Colon. Rectum. — 1999. Vol. 42. N 5.-P. 632−639.
- Arii S., Ishigami S., Mori A. et al. Implication of VEGF and MMPs in hepatic metastasis of human colon cancer. // Nippon. Geka. Gakka. i Zasshi. 1998. — Vol. 99.-N7.-P. 436−440.
- Arnold C.N., Blum H.E. Colon cancer: molecular markers. // Dtsch. Med.Wochenschr. -2005. Vol. 130. -N 14. — P. 880−882.
- Вакег E.A., Leaper D.J. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J. Cancer. — 2003. Vol. 39. -N 7. — P. 981−988.
- Baldus S.E. Clinical, pathological and molecular prognostic factors in colorectal carcinomas. // Pathologe. 2003. — Vol. 24. — N 1. — P. 49−60.
- Bandyopadhyay S., Zhan R., Chaudhuri A. et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. // Nat. Med. 2006. -Vol.12. — N 8. — P. 33 — 38.
- Bendardaf R., Lamlum H., Ristamaki R. CD44 variant 6 expression predicts response to treatment in advanced colorectal cancer. // Oncol.Rep. 2004. Vol. 11, N1, P.41−45.
- Bendardaf R., Lamlum H., Pyrhonen S. Prognostic and predictive molecular markers in colorectal carcinoma. // Anticancer Res. 2004 — Vol. 24. — N 4. — P. 2519−2530.
- Bendardaf R., Elzagheid A., Lamlum H. et al. E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer. // Oncol. Rep. 2005. — Vol. 13.-N5.-P. 831 -835.
- Bendardaf R., Algars A., Elzagheid A., et al. Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. // Oncol Rep. -2006. Vol. 16. -N4.-P. 741 -746.
- Bennett M.W., O’Connell J., Houston A., et al. Fas ligand upregulation is an early event in colonic carcinogenesis. // J. Cli. n Pathol. 2001. — Vol. 54. -N 8. — P. 598 604.
- Berney C.R., Yang J., Fisher R.J., et al. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. // Oncol Res. 1998. — Vol. 10. — N 1, P. 47- 54.
- Berney C.R., Yang J.L., Fisher R.J. et al. Overexpression of nm23 protein assessed by color video image analysis in metastatic colorectal cancer: correlation with reduced patient survival. // World J. Surg. -1998. Vol. 22. — N 5. P.484- 490.
- Berney C.R., Fisher R.J., Yang J. et al. Protein markers in colorectal cancer: predictors of liver metastasis. II Ann. Surg. 1999. — Vol. 230. — N 2. — P. 179 — 184.
- Berney C.R., Downing S.R., Yang J.L. et al. Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer. II J. Pathol. 2000. — Vol. 191. — P. l 5 — 20.
- Berney C.R., Fisher R.J., Yang J. et al. Genomic alterations (LOH, MI) on chromosome 17q21 -23 and prognosis of sporadic colorectal cancer. // Int. J. Cancer. //-2000.-Vol. 20.-N89(1).-P. 1−7.
- Berz D., Miner Т., McCormack E. et al. HER family inhibitors in pancreatic cancer: current status and future directions. // Expert. Opin. Ther. Targets. 2007. -Vol. 11.-N3.-P. 337−347.
- Bianco A.R., Carlomagno C., De Laurentiis M. et al. Prognostic factors in human colorectal cancer. // Tumori. 1997. — Vol. 83. — N 1. Supp. 1. — P. S15−18.
- Boedefeld W.M. 2nd, Bland K.I., Heslin MJ. Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. // Ann. Surg. Oncol. — 2003.-Vol. 10.-N8.-P. 839−851.
- Bosch F.X. Andl C., Abel U. et al. E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components. // Int. J. Cancer. 2005. — Vol. 114. — N 5. — P. 779 -790.
- Bosnar M.H., De Gunzburg J., Bago R. et al. Subcellular localization of A and В Nm23/NDPK subunits.// Exp. Cell Res. 2004. — Vol. 298. — N 1. — P. 275 -284.
- Brabletz Т., Jung A., Hermann K., et al. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. И Pathol. Res. Pract. 1998. — Vol. 194. — N 10. — P. 701−704.
- Brabletz Т., Jung A., Dag S., et al. Beta-catenin induces invasive growth by activating matrix metalloproteinases in colorectal carcinoma. // Verh. Dtsch. Ges. Pathol 2000. — Vol. 84. — P. 175 — 181.
- Brabletz Т., Jung A., Reu S. et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. // Proc. Natl. Acad. Sci. USA. -2001.-Vol. 98. -N 18.-P. 10 356−10 361.
- Brabletz T. The Rudolf Virchovv Prize 2001. The role of the oncoprotein beta-catenin in the progression of colorectal cancers. // Verh. Dtsch. Ges. Pathol. — 2001. -Vol. 85.-P. 243−249.
- Bralet M.P., Paule В., Falissard B. et al. Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas // Histopathology. 2007. — Vol. 50. — N 2. — P. 210−216.
- Brenner A.S., Thebo J.S., Senagore A.J., et al. Analysis of both NM23-H1 and NM23-H2 expression identifies «at-risk» patients with colorectal cancer. II Am. Surg.- 2003. Vol. 69. -N 3. — P. 203 — 208.
- Buglioni S., D’Agnano I., Cosimelli M., et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. // Int. J. Cancer. 1999. — Vol. 84. — N 6. — P. 545−552.
- Bukholm I.K., Nesland J.M. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. // Virchows Arch. 2000. — Vol. 436. — N 3. — P. 224 — 228.
- Bullions L.C., Levine A.J. The role of beta-catenin in cell adhesion, signal transduction, and cancer. II Curr. Opin. Oncol 1998. — Vol. 10. — N 1. — P. 81- 87.
- Cascinu S., Georgoulias V., Kerr D. et al. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. // Ann. Oncol -2003.-Vol. 14.-P. 25−29.
- Cavalot A., Martone Т., Roggero N. et al. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. // Head Neck. — 2007.
- Chakraborti S., Mandal M., Das S., et al. Regulation of matrix metalloproteinases: An overview. // Mol. CellBiochem. 2003. — Vol. 253. — P. 269 — 285.
- Cheah P.Y., Cao X., Eu K.W., et al. NM23-H1 immunostaining is inversely associated with tumour staging but not overall survival or disease recurrence in colorectal carcinomas. // Br. J. Cancer. 1998. — Vol. 77. — N7. P. 1164 — 1168.
- Chen J.Q., Zhan W.H., He Y.L., et al. Expression of heparanase gene, CD44v6, MMP7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. // World. J. Gastroenterol. 2004. — Vol. 10. — N 6. — P. 776 -782.
- Chen Y., Sasatomi E., Satoh T. Abnormal distribution of collagen type IV in extrahepatic bile duct carcinoma. // Pathol Int. 2000. — Vol. 5. — N 11. — P. 884 -890.
- Choi H.J., Jung I.K., Kim S.S., Hong S.H. Proliferating cell nuclear antigen expression and its relationship to malignancy potential in invasive colorectal carcinomas. // Dis. Colon Rectum. — 1997. — 40. N 1. — P. 51−55.
- Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. // J.O.P. 2007. — Vol. 9. — N 8(1). -P. 4−15.
- Coppola D., Hyacinthe M., Fu L., et al. CD44V6 expression in human colorectal carcinoma. // Hum. Pathol. 1998. Vol. 29, N6, P.627−635.
- Crowe P.J., Yang J.L., Berney C.R., et al. Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. // World J. Surg. 2001. — Vol. 25. — N 8. — P. 996 — 1001.
- Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. II J. Pathol. 1999. — Vol. 189. — P. 300 — 308.
- Curran S., Murray G.I. Matrix metalloproteinases: molecular aspects of their in tumour invasion and metastasis. // Eur. J. Cancer. 2000. — Vol.36. — N 13. P. 1621 -1630.
- Curran S., Dundas S.R., Buxton J., et al. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. // Clin. Cancer Res. 2004. — Vol.10. — N 24. — P. 8229 — 8234.
- Davies R.J., Miller R., Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. // Nat. Rev. Cancer. 2005. Vol. 5.-P. 199−209.
- Diez M., Medrano M., Muguerza J.M., et al. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas. I I Anticancer Res. 2000. — Vol. 20. — N 5. — P. 3907−3912.
- Dowsctt M., Cooke Т., Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? // Eur. J. Cancer. 2000. — Vol. 36. — P. 170 — 176.
- Duan G.J., Yan X.C., Bian X.W. The significance of beta-catenin and matrix metalloproteinase-7 expression in colorectal adenoma and carcinoma. // Zhonghua Bing LiXue Za Zhi. 2004. — Vol. 33. — N 6. — P. 518 — 522.
- Dukes C.E., Bussey H.J.R. The spread of rcctal cancer and its effect on prognosis. // Br. J. Cancer. 1958.- Vol.12. — P. 309−320.
- Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. II Nat. Rev. Cancer. 2002. — Vol. 2. — P. 161 — 174.
- El-Bahrawy M.A., Poulsom R., Jeffery R. et al. The expression of E-cadherin and catenins in sporadic colorectal carcinoma. // Hum. Pathol. 2001. — Vol. 32. — N 11. — P.1216−1224.
- Elzagheid A., Kuopio Т., Pyrhonen S., ct al. Lymph node status as a guide to sclcction of available prognostic markers in breast cancer: the clinical practicc of the future? // Diagn. Pathol. 2006. — Vol. 8. — N 1. — P 41.
- Engstrom P.F. Colorectal cancer. // Clinical Oncology. 2000. — P. 361 — 370.
- Fearnhcad N.S., Wilding J.L., Bodmer W.F. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis // Brit. Med. Bull. -2002.-Vol. 64.-P. 27−43.
- Fearon E.R., Vogelstein B. A gcnetic model for colorectal tumorigenesis. I I Cell. 1990. — Vol. 6. — P. 759 — 767.
- Feng G., Tan Y. Expression and significance of MMP2 and type IV collagen in gastric cancer. // Zhonghua Wai. Ke. Za. Zhi. 2000. — Vol. 38. — N 10. — P. 775 -777.
- Fcrnebro E., Bendahl P.O., Dictor M., et al. Immunohistochemical patterns in rcctal cancer: application of tissue microarray with prognostic correlations. // Int J Cancer. 2004. — Vol. 111. N 6. — P. 921−928.
- Forte A., D’Urso A., Gallinaro L.S. et al. Prognostic markers of the epithelial tumors of the large intestine. // Ann. Ital. Chir. 2002. — Vol. 73. — N 6. — P. 587 -596.
- Forte A., D’Urso A., Gallinaro L.S. NM23 expression as prognostic factor in colorectal carcinoma. // G. Chir. 2002. — Vol. 23. -N 3. — P. 61- 63.
- Fujita M., Khazenzon N.M., Bose S., et al. Overexpression of beta 1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases. // Breast Cancer Res. 2005. — Vol. 7. — N 4. — P. 411 — 421.
- Galbavy S., Lukac L., Porubsky J., et al. Collagen type IV in epithelial tumours of colon. II Acta Histochem. 2002. — Vol. 104. — N4. — P. 331 — 334.
- Gao Q.L., Ma D., Meng L., et al. Association between Nm23-Hl gene expression and metastasis of ovarian carcinoma. // AL Zheng. — 2004. Vol. 23. — N 6.-P. 650−654.
- Garinis G.A., Manolis E.N., Spanakis N.E., et al. High frequency of concomitant nm23-Hl and E-cadherin transcriptional inactivation in primary non-inheriting colorectal carcinomas. II J. Mol. Med. — 2003. — Vol. 81. N 4. — P. 256 -263.
- Gervaz P., Bouzourene H., Cerottini J.P., et al. Dukes В colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. // Dis. Colon Rectum. 2001. — Vol. 44. — N 3. — P. 364 — 372.
- Giatromanolaki A., Sivridis E., Stathopoulos G.P., et al. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse. II Anticancer Res. 2001. Vol. 21. — N1A. P. 253 — 259.
- Gilliland R-, Williamson K.E., Wilson R.H., et al. Colorectal cell kinetics. II Br. J. Surg. 1996. — Vol. 83. — N 6. — P. 739−749.
- Goncharuk V.N., del-Rosario A., Kren L., et al. Co-downregulation of PTEN, KAI-1, and nm23-Hl tumor/metastasis suppressor proteins in non-small cell lung cancer. // Ann. Diagn. Pathol 2004. — Vol. 8. — N 1. — P. 6 — 16.
- Gontero P., Banisadr S., Frea B. et al., Metastasis markers in bladder cancer: a review of the literature and clinical considerations. // Eur. Urol. — 2004. — Vol. 46. — N3.-P. 296−311.
- Gotley D.C., Fawcctt J., Walsh M.D., et al. Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. // Br. J. Cancer. 1996. — Vol. 74. — N 3. — P. 342 — 351.
- Graziano F., Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes" В colorectal cancer patients: how much evidence is enough? И Ann. Oncol. 2003. — Vol. 14. — P. 1026−1038.
- Greenlee R.T., Murray Т., Bolden S. et al. Cancer statistics 2000. // CA Cancer J. Clin. И 2000. Vol. 50. — P. 7 — 33.
- Gulubova M.V. Collagen type IV, laminin, alpha-smooth muscle actin (alphaSMA), alphal and alpha6 integrins expression in the liver with metastasesfrom malignant gastrointestinal tumours. // Clin Exp Metastasis. 2004. -Vol. 21. — N 6. — P. 485 — 494.
- Guzinska-Ustymowicz K., Chetnik A., Kemona A. Effects of changes at the site of E-cadherin expression as an indicator of colon cancer aggressiveness. // Rocz. Akad. Med. Bialymst. 2004. — Vol.49. Suppl 1. — P. 70 — 72.
- Half E., Broaddus R., Danenberg K.D., et al. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. // Int. J. Cancer. 2004. — Vol. 108. — N 4. — P. 540−548.
- Hayer J., Engel M., Seifert M. et al. Overexpression of nm23-H4 RNA in colorectal and renal tumours. // Anticancer Res. 2001. — Vol. 21. — N 4 A. — P. 2821 -2825.
- Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer // Oncogene. 2000. — Vol.19. — P. 6102 — 6114.
- Hayashida Y., Honda K., Idogawa M. et al. E-cadherin regulates the association between beta-catenin and actinin-4. // Cancer Res. 2005. — Vol. 65. — N 19. — P. 8836 — 8845.
- Hayer J., Engel M., Seifert M., et al. Overexpression of nm23-H4 RNA in colorectal and renal tumours. // Anticancer Res. 2001. — Vol. 21. — N 4A. — P. 2821 -2825.
- He S.Q., Zhang W.Y. Relationship between the expressions of Kail, nm23, ETS-1, VEGF and microvascular density and clinical significance in nasopharyngeal carcinoma. // Zhonghua Er Bi Yan Нои Той Jing Wai Ke Za Zhi. — 2006. — Vol. 41. -N11.-P. 813−817.
- Heide I., Thiede С., Poppe K. et al. Expression and mutational analysis of Nm23-Hl in liver metastases of colorectal cancer. // Br. J. Cancer. — 1994. Vol.70. -N6.-P. 1267−1271.
- Heisterkamp J., van Bommel J., Hop W.C. et al. P53 overexpression in colorectal metastases confincd to the liver and outcome of liver resection. // Hepatogastroenterology. 1999. — Vol. 46. N 30. — P. 3109−3114.
- Hewitt R.E., Powe D.G., Carter G.I., et al. Basement membrane collagen-IV synthesis in colorectal tumours. // Int. J. Cancer. 1992. — Vol. 51. — N 4. — P. 530 -536.
- Hewitt R.E., Powe D.G., Morrell K. Laminin and collagen IV subunit distribution in normal and neoplastic tissues of colorectum and breast. // Br. J. Cancer. 1997. — Vol. 75. — N 2. — P. 221 — 229.
- Heys S.D., Langlois N., Smith I.C., et al. NM23 gene product expression does not predict lymph node metastases or survival in young patients with colorectal cancer. // Oncol Rep. 1998. — Vol. 5. — N 3. — P. 735 -739.
- Hida J., Matsuda Т., Kitaoka M. et al. The role of basement membrane in colorectal cancer invasion and liver metastasis. // Cancer. 1994. — Vol. 74. — N 2. -P. 592 — 598.
- Hiendlmeyer E., Regus S., Wassermann S. et al. Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. // Cancer Res. 2004. — Vol. 64. -N 4. — P. 1209−1214.
- Hiki Y., Iyama K., Tsuruta J. et al. Differential distribution of basement membrane type IV collagen alpha 1 (IV), alpha2(IV), alpha5(IV) and alpha6(IV) chains in colorectal epithelial tumors. // Pathol. Int. 2002. — Vol. 52. — N 3. — P. 224 -233.
- Hipfner D.R., Cohen S.M. Connecting proliferation and apoptosis in development and disease. // Nat. Rev.Mol. Cell. Biol. 2004. — Vol. 5. — N 10. — P. 805−815.
- Hlubek F., Spaderna S., Jung A., et al. Beta-catenin activates a coordinated expression of the proinvasive factors laminin-5 gamma2 chain and MT1-MMP in colorectal carcinomas. // Int. J. Cancer. — 2004. — Vol. 108. — N 2. — P. 321−326.
- Holt P.R., Moss S.F., Kapetanakis A.M., et al. Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen? // Cancer Epidemiol. Biomarkers Prev. 1997. — Vol. 6. -N 2. — P. 131−135.
- Houlston R.S. What we could do now: molecular pathology of colorectal cancer // Mol. Pathol. 2001. — Vol. 54. — P. 206−214.
- Hsu N.Y., Chow K.C., Chen W.J. et al. Expression of nm23 in the primary tumor and the metastatic regional lymph nodes of patients with gastric cardiac cancer. // Clin. Cancer Res. 1999. — Vol. 5. — N 7. — P. 1752 — 1757.
- Hwang T.S., Han H.S., Choi H.K. et al. Differential, stagedependent expression of Hsp70, HspllO and Bcl-2 in colorectal cancer. // J. Gastroenterol. Hepatol. — 2003.-Vol. 18.- P. 690−700.
- Iacopetta B. Are there two sides to colorectal cancer? // Int. J. Cancer. 2002. -Vol. 101.-P. 403−408.
- Ichikawa W. Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer. // Pathobiology. 1994. — Vol. 62 — N 4. — P. 172 179.
- Iiizumi M., Bandyopadhyay S., Watabe K. Interaction of Duffy Antigen Receptor for Chemokines and KAI1: A Critical Step in Metastasis Suppression. // Cancer Res. — 2007. Vol. 67.-N4.-P. 1411 — 1414.
- Ikeguchi M., Makino M., Kaibara N. Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. // J. Surg. Oncol. — 2001. Vol. 77. -N3.- P. 201 -207.
- Illemann M., Bird N., Majeed A., et al. MMP 9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. // Mol. Cancer Res.- 2006. Vol. 4. — N 5. P. 293 — 302.
- Ilyas M., Hao X-P., Wilkinson K., et al. Loss of Bcl-2 expression correlates with tumor recurrence in colorectal cancer. // Gut. 1998. — Vol. 43. — P. 383−387.
- Indinnimeo M., Giarnieri E., Stazi A. et al. Early stage human colorectal cancer: prognostic value of nm23-Hl protein overexpression. //Cancer Lett. 1997.- Vol. l.-N 111(1−2). — P. 1−5.
- Indinnimeo M., Cicchini C., Giarnieri E., et al. Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. // Oncol. Rep. 2003. — Vol. 10. -N 6. — P.1875 — 1877.
- Ioachim E.E., Malamou-Mitsi V., Kamina S.A., et al. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. // Anticancer Res. — 2000. Vol. 20. — N 6B. — P. 4221−4225.
- Ishida T. Immunohistochemical expression of the CD44 variant 6 in colorectal adenocarcinoma. // Surg Today. 2000. — Vol. 30. — N 1. — P. 28 — 32.
- Jass J.J., Sobin L.H. Histological typing of intestinal tumours. // Geneva. World Health Organization. 1989. — 2 nd. ed. — P. 127.
- Ji S.Q., Ilua Y.W., Zhuang J., et al. Significance of COX-2, p53, proliferating cell nuclear antigen and nm23 expressions in gastric cancer and its behavior. // Ai. Zheng. 2002. — Vol. 21. — N 6. — P. 619 — 624.
- Johansson N., Ahonen M., Kahari V.M. Matrix metalloproteinases in tumor invasion. II. Cell Mol. Life ScL- 2000. Vol. 57. — P. 5 — 15.
- Joo M., Lee H.K., Kang Y.K. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis. // Anticancer Res. 2003. — Vol. 23. -N 2B. — P. 1581 — 1588.
- Jungling В., Menges M., Goebel R. et al. Expression of CD44v6 has no prognostic value in patients with colorectal cancer. // Z. Gastroenterol. 2002. — Vol. 40.-N4.-P. 229−233.
- Kahlenberg M.S., Sullivan J.M., Witmer D.D., Petrelli N.J. Molecular prognostics in colorectal cancer. Review. // Surg. Oncol. 2003. — Vol. 12. — N 3 — P. 173−186.
- Kamat A.A., Fletcher M., Gruman L.M., et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. // Clin. Cancer Res. — 2006. — Vol. 12.-N6.-P. 1707- 1714.
- Karakiulakis G., Papanikolaou C., Jankovic S.M., et al. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. II Invasion Metastasis. 1997. — Vol. 17. — N 3. — P. 158 — 168.
- Karamouzis M.V., Badra F.A., Papavassiliou A.G. Breast cancer: The upgraded role of HER-3 and HER-4. II Int. J. Biochem. Cell Biol. 2006.
- Kartenbeck J., Haselmann U., Gassier N. Synthesis of junctional proteins in metastasizing colon cancer cells. // Eur. J. Cell Biol. 2005. — Vol.84. -N 2−3. P. 417 -430.
- Kato К., Hara A., Kuno Т., et al. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. // J. Cancer Res. Clin. Oncol. 2005. — Vol. 131. — N 6. — P. 340 — 346.
- Khoursheed M.A., Mathew T.C., Makar R.R., et al. Expression of E-cadherin in human colorectal cancer. // Surgeon. 2003. — Vol. 1. — N 2. — P. 86 — 91.
- Kim J.C., Roh S.A. Kim H.C., et al. Coexpression of carcinoembryonic antigen and E-cadherin in colorectal adenocarcinoma with liver metastasis. // J. Gastrointest. Surg. 2003. — Vol.7. — N 7. — P. 931 — 938.
- Kim N.K., Park J.K., Lee K.Y., et al. P53, Bcl-2, and Ki 67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. // Ann. Surg. Oncol. 2001. — Vol. 8. — N 5. — P. 418−424.
- Kim T.D., Song K.S., Li G., et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. // BMC Cancer. 2006. — Vol. 6. — P. 211.
- Klapper L.N., Waterman I I., Sela M. et al. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of I IER-2 // Cancer Res. 2000. — Vol. 60. — P. 3384 — 3388.
- Kobielak A., Fuchs E. Alpha-catenin: at the junction of intercellular adhesion and actin dynamics. // Nat. Rev. Mol Cell. Biol 2004 — Vol. 5. — N 8. — P. 614 -625.
- Kovacevi D., Sonicki Z., Kusi Z., et al. Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer. // Int. J. Colorectal Dis. 2006.
- Kubben F.J., Peeters-Haesevoets A., Engels L.G., et al. Proliferating cell nuclear antigen (PCNA): a new marker to study human colonic cell proliferation. // Gut. 1994. — Vol. 35. -N 4. — P. 530−535.
- Kumar D.D., Kubota H., Tabara H. et al. nm23 in the primary and metastatic sites of gastric carcinoma. Relation to AFP-producing carcinoma. // Oncology. -1999.-Vol. 56.-N 2.-P. 122- 128.
- Lai C.H., Shan Y.S., Sy E.D. et al. The significance of CD44 expression in gastrointestinal neuroendocrine tumors. // Hepatogastroenterology. — 2005. Vol. 52. -N64.-P. 1071 — 1076.
- Langenskiold M., Holmdahl L., Falk P. et al. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. // Int. J. Colorectal Dis. 2005. — Vol. 20. — N 3. — P. 245 — 252.
- Lazaris ACh., Tzoumani A.N., Thimara I. et al. Immunohistochemical assessment of basement membrane components in colorectal cancer: prognostic implications. // Exp Clin Cancer Res. 2003. — Vol. 22, — N 4, — P. 599 — 606.
- Leahy D.T., Mulcahy H.E., O’Donoghue D.P., et al. Bcl-2 protein expression is associated with better prognosis in colorectal cancer. // Histopathology. — 1999. — Vol. 35.-N4.- P. 360−367.
- Lee J.C., Wang S.T., Chow N.H., et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. IIEur. J. Cancer. 2002. — Vol. 38. -N 8. — P. 1065 — 1071.
- Lee K.E., Lee H.J., Kim Y.H., et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. // Jpn. J. Clin. Oncol 2003. vol.33, N4, P. 173−179.
- Leeman M.F., Curran S., Murray G.I. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. // J. Pathol. 2003- 201 (4): 528−34.
- Li B.H., Zhao P., Liu S.Z., et al. Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. // World J. Gastroenterol. 2005. — Vol. 28. -N 20. — P. 3046 — 3050.
- Lim Y.J., Kim Y.H., Ahn G.H., et al. Cyclin E, p27 and mutant p53 do not predict the prognosis in AJCC stage II colorectal carcinomas. // Korean J. Gastroenterol. 2004. — Vol. 44. — N 6. — P. 314−320.
- Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers // Curr. Opin. Oncol. 2001. — Vol. 13. — P. 63−69.
- Lindmark G. NM-23 HI immunohistochemistry is not useful as predictor of metastatic potential of colorectal cancer. // Br J Cancer. 1996. — Vol. 74. — N 9. -P. 1413−1418.
- Liu Y.J., Yan P. S., Li J., et al. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. // World. J. Gastroenterol. 2005. — Vol. 11. — N 42.-P. 601−07.
- Lynch C.C., Matrisian L.M. Matrix metalloproteinases in tumor-host cell communication. // Differentiation. 2002. — Vol. 70. — P. 561 — 573.
- Magistrelli P., Coppola R., Tonini G., et al. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. II J. Cell Biochem. -2006. Vol. 1. -N 97(1). — P. 98 — 108.
- Mao J.D., Wu P., Xia X.H., et al. Correlation between expression of gastrin, somatostatin and cell apoptosis regulation gene bcl-2/bax in large intestine carcinoma. // World J. Gastroenterol. 2005. — Vol. 7. N 11(5). — P. 721 -725.
- Martinez J.A., Prevot S., Nordlinger В., et al. Overexpression of nm23-Hl and nm23-H2 genes in colorectal carcinomas and loss of nm23-Hl expression in advanced tumour stages. // Gut. -1995 Vol. 37. -N 57 P. 12 — 20.
- Matsuyama Y., Takao S., Aikou T. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorecD’l carcinomas. II J. Surg. Oncol. 2002. — Vol. 80.-N2.-P. 105- 110.
- Maurer C.A., Friess H., Kretschmann В., et al. Increased expression of егЬВЗ in colorectal cancer is associated with concomitant increase in the level of erbB2. // Hum. Pathol 1998. — Vol. 29. — N 8. — P. 771−777.
- Mook O.R., Frederiks W.M., Van Noorden C.J. The role of gelatinases in colorectal cancer progression and metastasis. // Biochim. Biophys. Acta. 2004. -Vol. 1705.-N2. — P. 69−89.
- Moran A., Iniesta P., Garcia-Aranda C., et al. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. // Oncol Rep. 2005. Vol. 13. — N1.-P. 115−120.
- Mori S., Ogata Y., Shirouzu K. Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis. // Int. J. Clin. Oncol. — 2004. Vol. 9. — N 4. P. 322 -329.
- Mottolese M., Buglioni S., Bracalenti C., et al. Prognostic relevance of altered Fas (CD95) — sestem in human breast cancer. // Int. J. Cancer. 2000. — Vol. 89. — N2.-P. 127−132.
- Muller W., Schneiders A., Hommel G., et al. Expression of nm 23 in gastric carcinoma: association with tumor progression and poor prognosis. // Cancer. 1998. — Vol. 15. — N83. — P. 2481 — 2487.
- Murray D., Morrin M., McDonnell S. Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. // Anticancer Res. 2004. — Vol.24. — N 2A. — P. 489 — 494.
- Mysliwiec A.G., Ornstein D.L. Matrix metalloproteinases in colorectal cancer. // Clin. Colorectal Cancer. 2002. — Vol. 1. -N 4. — P. 208−219.
- Nakajima I. Immunohistochemical study of the extracellular matrix in non-small cell lung cancer: relation to lymph node metastasis and prognosis. // Hokkaido Igaku Zasshi. 1991. — Vol. 66. — N 3, — P. 356 — 368.
- Nanashima A., Yamaguchi H., Sawai Т., et al. Prognostic factors in hepatic metastases of colorectal carcinoma: immunohistochemical analysis of tumor biological factors. // Dig. Dis. Sci. 2001. — Vol. 46. — N 8. — P. 1623 — 1628.
- Nasif W.A., Lotfy M., El-Sayed I.H., et al. Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer. // Med. Oncol. — 2006. -Vol. 23.-N2. P. 237−244.
- Neal C.P., Garcea G., Doucas H. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. // Eur. J. Cancer. 2006. — Vol. 42. -N 12. — P. 1728−1743.
- Nesi G., Palli D., Pernice L.M., et al. Expression of nm23 gene in gastric cancer is associated with a poor 5-year survival. // Anticancer Res. 2001. — Vol. 21. — N 5. — P. 3643 — 3649.
- Noguchi Т., Kikuchi R., Ono K., et al. Prognostic significance of p27/kipl and apoptosis in patients with colorectal carcinoma. // Oncol. Rep. — 2003. — Vol. 10. -N4.-P. 827−831.
- Offerhaus G.J., Giardiello F.M., Bruijn J.A., et al. The value of immunohistochemistiy for collagen IV expression in colorectal carcinomas. // Cancer. 1991. — Vol. 1. — N 67(1). — P. 99 — 105.
- Okada N., Ishida H., Murata N., et al. Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer. // Biochem. Biophys. Res. Commun.-2001.-Vol. 288.-N 1.-P. 212−216.
- Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimers in vivo with a conserved homolog, Bax, that accelerates programmed cell death. // Cell. 1993. -Vol.74. — P. 609−619.
- Ondruschka C., Buhtz P., Motsch C., et al. Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. // Pathol. Res. Pract. 2002. — Vol. 198. — N 8. — P. 50 915.
- Ougolkov A., Yamashita K., Bilim V., et al. Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. //Int J Colorectal Dis. 2003. -Vol. 18. N 2. — P. 160−167.
- Paik K.H., Park Y.H., Ryoo B.Y., et al. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer. II J. Korean Med. Sci. 2006. — Vol. 21. — N 1. — P. 35 — 39.
- Papadopoulou S., Scorilas A., Arnogianaki N., et al. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. // Tumour Biol. — 2001. -Vol. 22. N 6. — P. 383 — 389.
- Parsons S.L., Watson S.A., Collins H.M., et al. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. // Br. J. Cancer. 2000. — Vol. 82. N 1. -P. 249.
- Pasche В., Mulcahy M., Benson A.B. 3rd. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment Review. // Best. Pract. Res. Clin. Gastroenterol. 2002. — Vol. 16. — N 2.- P. 331−345.
- Paul-Samojedny M., Kokocinska D., Samojedny A., et al. Expression of cell survival/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis. // Biochim Biophys Acta. 2005. — Vol. 30. — N 1741(1−2). P. 25 — 29.
- Peduto Eberl L., Guillou L., Saraga E., et al. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. // Int. J.Cancer. 1999. — Vol. 81. -N 5. — P. 772−778.
- Petrowsky H., Sturm I., Graubitz O., et al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. // Eur. J. Surg. Oncol. — 2001.-Vol. 27.-N 1. P.80−87.
- Piard F., Martin L., Chapusot C., et al. New histologic prognostic factors in colorectal cancer. // Gastroenterol. Clin. Biol. 2002. — Vol. 26. 5 Suppl. — P. B62−73.
- Piccart M.J., Di Leo A., Hamilton A. HER2: a 'predictive factor' ready to use in the daily management of breast cancer patients? // Eur. J. Cancer. 2000. vol. 36, -P. 1755- 1761.
- Popat S., Chen Z., Zhao D. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. II Ann. Oncol. 2006. — Vol. 17. — N 12. — P. 1810−1817.
- Polychronidis A.C., Tsaroucha A.K. Anagnostoulis S.K., et al. Serum levels of c-erbb-2 correlate with advanced stage and liver metastasis in colorectal cancer. // Folia Med. 2003.-Vol. 45.-N2.-P. 12−16.
- Rampino N., Yamamoto H., Ionov Y., et al. Somatic frameshifl mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. // Science. -1997.-N275.-P. 967- 969.
- Resnick M.B., Routhier J., Konkin Т., et al. Epidermal growth factor receptor, c-MET, Б-Catenin, and p53 expression as prognostic indicators in stage II colon cancer. // Clin. Cancer Res. 2004. — Vol. 10. — P. 3069 — 3075.
- Reinacher-Schick A., Baldus S.E., Romdhana В., et al. Loss of Smad4 correlates with loss of the invasion suppressor E-cadherin in advanced colorectal carcinomas. II J. Pathol. 2004. — Vol. 202. — N 4. — P. 412 — 420.
- Rosati G., Chiacchio R., Reggiardo G., et al. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. // Tumour Biol 2004. — Vol. 25. — N 5−6. — P. 258 — 263.
- Rubin I., Yarden Y. The basic biology of HER2. Review. // Ann. Oncol. -2001.- Vol. 12. Suppl 1. P. S3−8.
- Rundhaug J.E. Matrix metalloproteinases and angiogenesis. // J. Cell Mol. Med. 2005. — Vol. 9. — N 2. — P. 267 — 285.
- Ryan A.E., Shanahan F., O’Connell J., et al. Fas ligand promotes tumor immune evasion of colon cancer in vivo. // Cell Cycle. 2006. — Vol. 5. — N 3. — P. 246−249.
- Saito H., Osaki Т., Murakami D., at al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. // J. Surg. Oncol. 2007. -Vol. 1.- N95(2).- P. 123- 128.
- Saito N., Kameoka S. Serum laminin is an independent prognostic factor in colorectal cancer. // Int. J. Colorectal Dis. 2005. — Vol. 20. — N 3. — P. 238 — 244.
- Saito Т., Masuda N., Miyazaki Т., et al. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. // Oncol Rep. 2004. — Vol. 11. N3.-P. 605−611.
- Santini D., Tonini G., Vecchio F.M., et al. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. // J. Clin. Pathol 2005. — Vol. 58. — N 2. — P. 159 — 165.
- Sarris M., Lee C.S. Nm 23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver. // Eur. J. Surg. Oncol. 2001. — Vol. 27. — N 2. -P. 170- 174.
- Saw R.P., Koorey D., Painter D., et al. P53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. // Br. J. Surg. -2002. Vol. 89. N 11. — P. 1409−1415.
- Schelwies K., Sturm I., Grabowski P., et al. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. // Int. J. Cancer. 2002. — Vol. 99. — N 4. — P. 589 — 599.
- Scott N., Sagar P., Stewart J., et.al. P53 in colorectal cancer: clinicopathological correlation and prognostic significance. // Br.J.Canc. — 1991. Vol. — 63. — P. 317 -319.
- Sharma S.V., Bell D.W. Settleman J., at al. Epidermal growth factor receptor mutations in lung cancer. // Nat. Rev. Cancer. 2007 — Vol. 1- N 3. — P. 169−181.
- Sheikh H., Murphy J., Hunt JL. NM-23 gene loss of heterozygosity and protein expression in high-stage laryngeal squamous cell carcinomas. // Diagn. Mol. Pathol. -2006.-Vol. 15.-N 1. P. 1 -6.
- Shimokawa K., Inada K. Advances of immunohistochemistiy and its application to histopathology studies on liver metastasis of colorectal carcinoma -venous basement membrane laminin. // Rinsho Byori. — 1990. — Vol. 38. — N2. — P. 115 — 23.
- Shinto E., Mochizuki H., Ueno H., et al. A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci. // Histopathology. 2005. — Vol. 47. — N 1. — P. 25 — 31.
- Shiraki K., Tsuji N., Shioda Т., et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. // Proc. Natl. Acad. Sci. USA.— 1997. Vol. 94. -N 12. — P. 6420−6425.
- Sis В., Sagol O., Kupelioglu A., et al. Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. // Pathol. Res. Pract. 2004. — Vol. 200. -N 5. — P. 379 — 387.
- Smyth E.F., Sharma A., Sivarajasingham N., et al. Prognostic implications of hMLHl and p53 immunohistochemical status in right-sided colon cancer. // Dis. Colon Rectum. -2004. -Vol.47.-N 12. P.2086 — 2091.
- Sokmen S., Lebe В., Sarioglu S., et al. Prognostic value of CD44 expression in colorectal carcinomas. II Anticancer Res. 2001. — Vol. 21. — N 6A. — P. 4121 — 4126.
- Song E., Chen J., Ouyang N., et al., Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. И Br. J. Cancer. 2001. Vol. 85. -N 7. P. 1047−1054.
- Soreide K., Janssen E.A., Korner H., Baak J.P. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. // J. Pathol. 2006. — Vol. 209. — N 2. — P. 147−156.
- Spindler K.L., Olsen D.A., Nielsen J.N. Lack of the type III epidermal growth factor receptor mutation in colorectal cancer. II Anticancer Res. —2006. Vol. 26. — N 6C. — P. 4889−4893.
- Srinivasan R., Gillett C.E., Barnes D.M., et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers // Cancer Res. 2000. -Vol. 60.-P. 1483- 1487.
- Stark A.M., Tongers K., Maass N, et al. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. // J. Cancer Res. Clin. Oncol. -2005.-Vol. 131.-N 3. P. 191 — 198.
- Steffensen K.D., Waldstrom M., Jeppesen U., et al. The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. // Int.J. Gynecol. Cancer. 2007.
- Sun X.F., Carstensen J.M., Stal O., et al. Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2, p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. // Int. J. Cancer. — 1996. — Vol. 69. N 1. — P. 5−8.
- Takahashi M., Kataoka S. Development of anti cancer drugs targeted on Fas-mediated apoptosis signal. // Gan. To.Kagaku. Ryoho. — 1997. — Vol. 24. N 2. — P. 222−228.
- Terada R., Yasutake Т., Nakamura S., et al. Clinical significance of nm 23 expression and chromosome 17 numerical aberrations in primary gastric cancer. // Med. Oncol 2002. — Vol. 19. -N 4. — P. 239−248.
- Tien Y.W., Jeng Y.M., Hu R.H., et al. Intravasation-related metastatic factors in colorectal cancer. // Tumour Biol. 2004. — Vol. 25. — N 1−2. — P. 48 — 55.
- Tomic S., Ilic Forko J., Babic D., et al. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. // Croat. Med. J. -2003. Vol. 44. — N 4. — P. 429−434.
- Tollenaar R.A., van Krieken J.H., van Slooten H.J., et al. Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. // Br. J. Cancer. 1998. — Vol. 77. — N 11. — P. 1842−18 427.
- Tomita Т., Iwata K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. // Dis. Colon Rectum. -1996.-Vol. 39.-Nil.-P. 1255−1264.
- Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. // Biochimie. — 2005. Vol. 87. -N 3−4. — P. 287−297.
- Tutton M.G., George M.L., Eccles S.A., et al. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. // Int. J. Cancer. 2003. — Vol. 107. -N 4. — P. 541−550.
- Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. // Circ. Res. 2003. —Vol. 92. — P. 827−839.
- Vogel I., Soeth E., Ruder C., et al. Disseminated Tumor cells in the blood and|or bone marrow of patients with colorectal carcinoma are an independent prognostic factor // Ann. Oncol. 2000. — Vol. 11. — P. 183.
- Vogelstein В., Fearon E.R., Hamilton S.R., et.al. Genetic alterations during colorectal tumor development. UN. Engl. J. Med. 1988. — P. 319 — 525.
- Waas E.T., Wobbes Т., Lomme R.M., et al. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. // Br. J. Surg. 2003. Vol. 90.-N 12.-P. 1556- 1564.
- Waas E.T., Wobbes T. Ruers Т., et al. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. // Eur J Surg Oncol. 2006. Vo. 32. — N 7. — P. 756−63.
- Wadler S. Targeted therapy in colorectal cancer. // Clin Colorectal Cancer. — 2007. Vol. 6. — N 5. — P. 357−361.
- Wang X., Zhang S., MacLennan G.T., et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. // Clin. Cancer Res. 2007. — Vol. 13. — N 3. — P. 953−957.
- Weg-Remers S., Anders M., von Lampe В., et al. Decreased expression of CD44 splicing variants in advanced colorectal carcinomas. // Eur. J. Cancer. — 1998. -Vol. 34.-N 10.-P. 1607- 1611.
- Widel MS, Widel M. Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer. // Postepy Hig. Med. Dosw. -2006. Vol. 60. — P. 453−470.
- Wielenga V.J., van der Voort R., Mulder J.W., et al. CD44 splice variants as prognostic markers in colorectal cancer. // Scand. J. Gastroenterol. 1998. — Vol. 33.-N l.-P. 82−87.
- Wijnhoven B.P., Dinjens W.N., Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. // Br. J. Surg. — 2000. Vol. 8, — N 8, — P. 992 -1005.
- Wilmanns C., Grossmann J., Stcinhauer S., et al. Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients. // Clin. Ex. Metastasis. — 2004. Vol. 21. N 1. — P. 75−78.
- Wittig B.M., Goebel R., Weg-Remers S., et al. Stage-specific alternative cplicing of CD44 and alpha 6 beta 1 integrin in colorectal tumorigenesis. // Exp. Mol. Pathol. 2001. — Vol. 70. — N 2. — P. 96 — 102.
- Woessner J.F.J. Matrix metalloproteinases and their inhibitors in connectivc tissue remodeling. IIFASEBJ. 1991. — Vol. 5. — P. 2145−2154.
- Wolf H.K., Stober C., Hohenfellner R., Leissner J. Prognostic value of p53, p21/WAFl, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pTl G3 urothelial bladder carcinomas. // Tumour Biol. 2001. — Vol. 22. — N 5. — P. 328−333.
- Yamada H., Kondo S., Okushiba S., et al. Analysis of predictive factors for recurrence after hepatectomy for colorectal liver metastases. // World J. Surg. 2001. -Vol. 25.-N9.-P. 1129−1133.
- Yamaguchi A., Kurosaka Y., Fushida S., et.al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. // Cane. 1992. —Vol. 70. — P. 2778 — 2784.
- Yamaguchi A., Urano Т., Fushida S., et al. Inverse association of nm23-Hl expression by colorectal cancer with liver metastasis. // Br. J. Cancer. 1993. — Vol. 68.-N5.-P. 1020- 1024.
- Yamane N., Tsujitani S., Makino M., et al. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer. // Oncology. 1999. — Vol. 56. -N3.-P. 232−238.
- Yang J.L., Ow K.T., Russell P.J., et al. Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. II Ann. Surg. Oncol. — 1996. Vol. 3.-N6.-P. 574−579.
- Yang J.L., Hanley J.R., Yu Y., et al. In vivo overexpression of c-erbB-2 oncoprotein in xenografts of mice implanted with human colon cancer lines. // Anticancer Res. 1997. Vol.17. — N 5A. — P. 3463−3468.
- Yarden Y., Sliwkowski M.X. Untangling the ErbB signaling network. // Nat. Rev. Mol. Cel. Biol. 2001. — Vol. 2. — N 2.- P. 127−137.
- Yasuda M., Nakano K., Yasumoto K., Tanaka Y. CD44: functional relevance to inflammation and malignancy. Review .// Histol. Histopathol. 2002. — Vol. 17. — N 3.-P. 945−950.
- Yoo C.H., Noh S.H., Kim H., et al. Prognostic significance of CD44 and nm23 expression in patients with stage II and stage IIIA gastric carcinoma. // J. Surg. Oncol. 1999. — Vol. 71. -N 1. — P. 22 — 28.
- Yoon S.O., Park S.J., Yun C.H., et al. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. II J. Biochem. Mol. Biol. 2003. — Vol. 36. P. 128 — 137.
- Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies// Oncogene. 2000. — Vol.19. — P. 6115−6121.
- Zavrides H.N., Zizi-Sermpetzoglou A., Panousopoulos D., et al. Prognostic evaluation of CD44 expression in correlation with bcl-2 and p53 in colorectal cancer. // Folia Histochem. Cytobiol. 2005. Vol. 43. — N 1. — P. 31 — 36.
- Zeng Z.S., Hsu S., Zhang Z.F., et al. High level of Nm23-Hl gene expression is associated with local colorectal cancer progression not with metastases. // Br. J. Cancer. 1994. — Vol. 70. — N 5. — P. 1025 — 1030.
- Zetter B.R. Adhesion molecules in tumor metastasis. // Sem. Cane. Biol. 1993. -Vol. 4.-P. 219−229.
- Zhang В., Ougolkov A., Yamashita K. Beta-Catenin and ras oncogenes detect most human colorectal cancer. // Clin. Cancer Res. — 2003. — Vol. 9. N 8. P. 3073.
- Zhang L., Yu J., Park В. H., et al. Role of BAX in the apoptotic response to anticancer agents. // Science. 2000. — Vol. 290. — P. 989−992.
- Zhou L., Xic M., Zhou J.Q., et al. 67-kDa laminin receptor in human laryngeal squamous cell carcinoma. // Laryngoscope. 2006. — Vol. 116, — N 1, — P. 28 — 32.
- Zhu Q., Liu .J.Y, Xu H.W., et al. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. // World J. Gastroenterol. 2005. — Vol. 11.-N39.-P. 6125−6129.
- Zucker S., Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. // Cancer Metastasis Rev. 2004. — Vol. 23. — N 1−2. — P. 101 — 117.